Analysis of Initial Baseline Clinical Parameters and Treatment Strategy Associated with Medication Failure in the Treatment of Benign Prostatic Hyperplasia in Korea
1
조회
0
다운로드
2
인용
0
참고문헌
초록
Purpose: To analyze the baseline clinical factors and medication treatment strategy used in cases with medication treatment failure of benign prostatic hyperplasia (BPH). Methods: From January 2006 to December 2009, 677 BPH patients with at least 3 months of treatment with medication were enrolled. We analyzed clinical factors by medication failure (n=161) versus maintenance (n=516), by prostate size (less than 30 g, n=231; 30 to 50 g, n=244; greater than 50 g, n=202), and by prostate-specific antigen (PSA) levels (less than 1.4 ng/mL, n=324; more than 1.4 ng/mL, n=353). Results: Age, combination medication rate, PSA, and prostate volume were statistically different between the medication treatment failure and maintenance groups. By prostate size, the PSA and medication failure rates were relatively higher and the medication period was shorter in patients with a prostate size of more than 30 g. The combination medication rate was higher in patients with a prostate size of more than 50 g. The medication failure rate and prostate volume were higher in patients with a PSA level of more than 1.4 ng/mL. However, the combination treatment rate was not significantly different in patients with a PSA level lower than 1.4 ng/mL. Suggestive cutoffs for combination medication are a prostate volume of 34 g and PSA level of 1.9 ng/mL. Conclusions: The clinical factors associated with medication failure were age, treatment type, and prostate volume. Combination therapy should be considered more in Korea in patients with a PSA level higher than 1.4 ng/mL and a prostate volume of between 30 and 50 g to prevent medication failure.
Abstract
Purpose: To analyze the baseline clinical factors and medication treatment strategy used in cases with medication treatment failure of benign prostatic hyperplasia (BPH). Methods: From January 2006 to December 2009, 677 BPH patients with at least 3 months of treatment with medication were enrolled. We analyzed clinical factors by medication failure (n=161) versus maintenance (n=516), by prostate size (less than 30 g, n=231; 30 to 50 g, n=244; greater than 50 g, n=202), and by prostate-specific antigen (PSA) levels (less than 1.4 ng/mL, n=324; more than 1.4 ng/mL, n=353). Results: Age, combination medication rate, PSA, and prostate volume were statistically different between the medication treatment failure and maintenance groups. By prostate size, the PSA and medication failure rates were relatively higher and the medication period was shorter in patients with a prostate size of more than 30 g. The combination medication rate was higher in patients with a prostate size of more than 50 g. The medication failure rate and prostate volume were higher in patients with a PSA level of more than 1.4 ng/mL. However, the combination treatment rate was not significantly different in patients with a PSA level lower than 1.4 ng/mL. Suggestive cutoffs for combination medication are a prostate volume of 34 g and PSA level of 1.9 ng/mL. Conclusions: The clinical factors associated with medication failure were age, treatment type, and prostate volume. Combination therapy should be considered more in Korea in patients with a PSA level higher than 1.4 ng/mL and a prostate volume of between 30 and 50 g to prevent medication failure.
참고문헌 (14)
- Roehrborn CG, "Benign prostatic hyperplasia: an overview", Rev Urol, 7(Suppl 9), pp.3~14 (2005)
- Hong SJ, "Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study", Eur Urol, 44, pp.94~99 (2003)
- McConnell JD, "The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group", N Engl J Med, 338, pp.557~563 (1998)
- Emberton M, "Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe:The Prostate Research on Behaviour and Education (PROBE) Survey", Int J Clin Pract, 62, pp.18~26 (2008)
- Emberton M, "Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management", Int J Clin Pract, 62, pp.1076~1086 (2008)
- MacDonald R, "Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects", Urology, 66, pp.780~788 (2005)
- Roehrborn CG, "Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2(dutasteride) in men with benign prostatic hyperplasia", Urology, 60, pp.434~441 (2002)
- McConnell JD, "The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia", N Engl J Med, 349, pp.2387~2398 (2003)
- Madersbacher S, "EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines)", Eur Urol, 46, pp.547~554 (2004)
- Anderson JB, "The progression of benign prostatic hyperplasia: examining the evidence and determining the risk", Eur Urol, 39, pp.390~399 (2001)
- Kirby RS, "Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia:the Prospective European Doxazosin and Combination Therapy(PREDICT) trial", Urology, 61, pp.119~126 (2003)
- Jacobsen SJ, "Natural history of prostatism: risk factors for acute urinary retention", J Urol, 158, pp.481~487 (1997)
- Lepor H, "The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group", N Engl J Med, 335, pp.533~539 (1996)
- Roehrborn CG, "Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials", Urology, 58, pp.210~216 (2001)